Lung adenocarcinoma (LADC) premalignancy remains poorly understood, and diagnostic biomarkers are lacking. Scafoglio et al. analyse 58 human LADC samples and note that sodium glucose transporter 2 (SGLT2) is predominantly expressed in human premalignant and early-stage LADCs. Similarly, both expression and functional activity of SGLT2 were high in premalignant and early-stage LADC in genetically engineered mouse models (GEMMs) and patient-derived xenografts (PDXs). Oral treatment with the SGLT2 inhibitor canagliflozin — used to treat type 2 diabetes — delayed the onset of tumours and increased survival of GEMMs and reduced tumour volume in PDX models of LADC.
References
Scafoglio, C. et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci. Transl Med. 10, eaat5933 (2018)10.1126/scitranslmed.aat5933.
Rights and permissions
About this article
Cite this article
Crunkhorn, S. Repurposing SGLT2 inhibitors. Nat Rev Drug Discov 18, 18 (2019). https://doi.org/10.1038/nrd.2018.229
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.229
